At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 55 enrolled
Drug / intervention
Injections of tildrakizumabdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-Label, Real World Study Evaluating the Long-Term Quality of Life of Tildrakizumab in Adult Patients With Moderate to Severe Plaque Psoriasis
In Brief
A Phase 4 clinical trial evaluating Injections of tildrakizumab for Psoriasis. Completed, enrolled 55 participants across 2 sites.
Detailed Summary
This is a Phase 4 multicenter, uncontrolled open-label study design. There will be a total of 10 study visits at Screening, Baseline, Week 4, Week 8, Week 12, Week 16, Week 28, Week 40, Week 52 and Week 64, with subjects receiving tildrakizumab injections at Week 0, Week 4, Week 16, Week 28, Week 40, and Week 52. The total study duration will be approximately 64 weeks, excluding a screening period.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPsoriasis
CountriesUnited States
Collaborators--
Timeline
Phase 4CompletedFinished
20192020202120222023202420252026
First PostedOct 2018
Enrollment StartJul 2019
Primary CompletionNov 2021
Study CompletionNov 2021
TodayJul 2026
First PostedOct 24, 2018
Enrollment StartJul 16, 2019
Primary CompletionNov 2, 2021
Study CompletionNov 5, 2021
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 7.7 years ago
Interventions
Injections of tildrakizumabdrug
given at Week 0, Week 4, Week 16, Week 28, Week 40 and Week 52